According to a recent LinkedIn post from C Ray Therapeutics, the company’s team plans to attend ANZSNM 2026 in Canberra from May 15–17, positioning itself within a key regional forum for nuclear medicine professionals. The post highlights that representatives will be available at Booth #48 and are seeking conversations with stakeholders across radiopharmaceutical development, supply, and clinical translation in the Asia-Pacific market.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post suggests a focus on potential partnerships around Cu-64 and Ac-225 supply, as well as engagement with parties working through IND-stage CMC considerations. For investors, this outreach could indicate efforts to deepen C Ray Therapeutics’ integration into nuclear medicine supply chains, expand its collaboration network, and potentially secure future commercial or development agreements in the Asia-Pacific radiopharmaceutical and theranostics ecosystem.
The message also references interest in China’s RDC ecosystem, implying that C Ray Therapeutics may be tracking or exploring opportunities linked to that market’s infrastructure and capabilities. If these discussions translate into concrete partnerships or service mandates, they could support the company’s growth trajectory as a contract research, development, and manufacturing-oriented player in radiopharmaceuticals, although no specific deals or financial terms are mentioned in the post.